Correction of anaemia with darbepoetin alfa in patients with chronic kidney desease receiving dialysis

Nephrology Dialysis Transplantation

Volumn 18, Issue 3, 2003, Pages 576-581

  Macdougall, Iain C ^a   Matcham, James ^b   Gray, Stephen J ^b   Bargman, J ^c   Barre, P ^d   Coles, G A ^e   Gokal, R ^f   Jindal, K ^g   Maxwell, A P ^h   Mignon, F ⁱ   Richardson, R ^c   Tomson, C ^j   Walls, J ^k   Winearls, C ^l  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b AMGEN LTD   (United Kingdom)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e Cardiff Royal Infirmary   (United Kingdom)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^g Prince Edward Island   (Canada)

^h BELFAST CITY HOSPITAL   (United Kingdom)

ⁱ BICHAT HOSPITAL   (France)

^j SOUTHMEAD HOSPITAL   (United Kingdom)

^k LEICESTER GENERAL HOSPITAL   (United Kingdom)

^l NONE

more..

Author keywords

Anaemia; Chronic kidney disease; Darbepoetin alfa; Dialysis; Novel erythropoiesis stimulating protein

Indexed keywords

ARANSEP; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ANTIBODY SCREENING; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPOTENSION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PERIPHERAL EDEMA; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOSIS; VOMITING;

ADULT; AGED; ANEMIA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS; TIME FACTORS;

EID: 0037338670     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/18.3.576     Document Type: Article

References (20)

1. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 1: 1175-1178
2. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-78
3. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989; 38: 863-899
4. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416
5. Macdougall IC, Roberts DE, Neubert P et al. Pharmacokinetics of intravenous, intraperitoneal and subcutaneous recombinant erythropoietin in patients on CAPD. Contrib Nephrol 1989; 76: 112-121
6. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dialysis Transplant 1999; 14 [Suppl 5]: 1-50
7. Egrie JC, Browne JK. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 [Suppl 1]: 3-10
8. Macdougall IC, Gray SJ, Elston O et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with Epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392-2395
9. NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 1997; 30: S192-S240
10. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76-89
11. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Int Med 1989; 111: 992-1000
12. Egrie JC, Browne JK. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 [Suppl 3]: 3-13
13. Weiss LG, Clyne N, Divino Fihlho J et al., on behalf of the Swedish Study Group. The efficiency of once weekly compared with two and three times weekly subcutaneous Epoetin beta: results from a randomized controlled multicentre trial. Nephrol Dialysis Transplant 2000; 15: 2014-2019
14. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL on behalf of the Study Group. Once-weekly compared with three-times-weekly subcutaneous epoetin β: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119-125
15. Andrulli S, D'Aminco M, Locatelli F. Is the use of subcutaneous epoetin β once a week really equivalent to a more frequent adminstration of the same total dose? Nephrol Dialysis Transplant 2001; 16: 2439-2440
16. Locatelli F, Olivares J, Walker R et al., on behalf of the European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747
17. Coyne D, Ling BN, Toto R et al. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO). J Am Soc Nephrol 2000; 11: 1380A
18. Vanrenterghem Y, Barany P, Mann JF et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175
19. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110-118
20. Graf H, Lacombe JL, Braun J et al. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin when adminstered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in dialysis patients. J Am Soc Nephrol 2000; 11: 250A